Directed cardiomyocyte differentiation of human induced pluripotent stem cells (hPSCs) is a major tool for development of disease models, drug screening platforms, and cellular therapies. Our workflow offers consistent, timesaving, and reliable hPSC differentiation solutions resulting in cardiomyocytes ready for any downstream application.
With a focus on maintaining consistency, viability and reliability of cells, our workflow is inclusive of solutions for cell differentiation, culture, isolation and characterization and thus enables the differentiation of cells for further applications.
hPSCs, either human induced pluripotent stem cells (iPSC) or embryonic stem cells (ES cells), are initially expanded in StemMACS™ iPSC-Brew XF, human or StemMACS PSC-Brew XF, human, allowing the cells to maintain a highly pluripotent phenotype making them well suited for differentiation into any cell type, such as cardiomyocytes.
StemMACS CardioDiff Kit XF, human has been designed to ease iPSC differentiation to cardiomyocytes in just eight days.
This ready-to-use and xeno-free cell culture system ensures high differentiation efficiency with no additional patterning factors, providing you an easy to follow protocol to maintain strong experiment-to-experiment consistency.
StemMACS CardioDiff Kit XF, human can be used with adherent PSC cultures to obtain a monolayer of highly functional PSC-derived cardiomyocytes. Additionally, it can be used to differentiate three-dimensional PSC aggregates into beating cardiospheres.
StemMACS CardioDiff Kit XF, human leads to the generation of ventricular-like cardiomyocytes and, if supplemented with retinoic acid, to atrial-like cardiomyocytes.
hPSC-derived cardiomyocytes can be further maintained with StemMACS Cardiac Cultivation Medium XF, human for up to 30 days. If cells need to be stored for a longer time, they should be cryopreserved in StemMACS Cryo-Brew to maintain their integrity.
After thawing, cardiomyocytes should be cultured in StemMACS Cardiac Cultivation Medium XF, human to ensure a fast recovery. In both cases, hPSC-derived cardiomyocytes keep on expressing characteristic markers and show typical morphology.
To ensure reliable experimental results, it is critical to work with highly homogeneous cultures of correctly differentiated PSC-derived cardiomyocytes. For this reason, we have developed the PSC-Derived Cardiomyocyte Isolation Kit, human which in contrast to other metabolic selection methods, does not induce any phenotype changes and delivers good yields of highly viable and functional cardiomyocytes.
Based on magnetic cell separation, PSC-derived non-cardiomyocytes are depleted first before enriching PSC-derived cardiomyocytes in a second step . This not only provides a fast method (45–90 minutes), but also consistently delivers pure cardiomyocyte populations (up to 97% purity) independent of the differentiation protocol, hPSC line used, time point, or efficacy of differentiation.
PSC-derived cardiomyocytes comprise a variety of subtypes or subpopulations, such as atrial-like, ventricular-like, and pacemaker-like cells. Characterization has been traditionally done by lengthy and difficult electrophysiological analysis of the respective cell cultures. By contrast, adopting a flow-cytometric characterization approach provides a simpler and time-saving alternative for qualitative and quantitative analysis.
Our flow cytometry panel for the characterization of PSC-derived cardiomyocyte populations is based on novel recombinantly engineered cardiomyocyte-specific REAfinity™ Antibodies that additionally allow the detection of ventricular and atrial subpopulations.